Alice Chen

2.8k total citations · 1 hit paper
14 papers, 1.8k citations indexed

About

Alice Chen is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Alice Chen has authored 14 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Cancer Research and 3 papers in Molecular Biology. Recurrent topics in Alice Chen's work include Cancer Genomics and Diagnostics (3 papers), PARP inhibition in cancer therapy (2 papers) and Acute Myeloid Leukemia Research (1 paper). Alice Chen is often cited by papers focused on Cancer Genomics and Diagnostics (3 papers), PARP inhibition in cancer therapy (2 papers) and Acute Myeloid Leukemia Research (1 paper). Alice Chen collaborates with scholars based in United States, Canada and France. Alice Chen's co-authors include Janet Dancey, F. Stephen Hodi, Elisabeth G.E. de Vries, Lalitha Shankar, Patrick Therasse, Jan Bogaerts, Sumithra J. Mandrekar, Nancy U. Lin, Lesley Seymour and Lawrence H. Schwartz and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Alice Chen

13 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

2017 1.5k citations Lesley Seymour, Jan Bogaerts et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alice Chen United States	7	1.3k	624	346	332	241	14	1.8k
Daniel L. Suzman United States	19	1.3k 1.0×	812 1.3×	318 0.9×	219 0.7×	272 1.1×	59	2.0k
Marc Van den Eynde Belgium	21	972 0.7×	347 0.6×	246 0.7×	359 1.1×	331 1.4×	90	1.6k
Vincent van der Noort Netherlands	23	1.3k 1.0×	1.4k 2.3×	294 0.8×	332 1.0×	286 1.2×	133	2.5k
Édith Borcoman France	17	948 0.7×	419 0.7×	281 0.8×	152 0.5×	150 0.6×	50	1.3k
Oliver Bohnsack United States	5	2.0k 1.5×	700 1.1×	957 2.8×	300 0.9×	154 0.6×	12	2.4k
Gianluca Spitaleri Italy	26	1.1k 0.9×	985 1.6×	313 0.9×	403 1.2×	151 0.6×	83	2.1k
Stefan Diem Switzerland	17	2.2k 1.7×	629 1.0×	625 1.8×	117 0.4×	207 0.9×	31	2.6k
Miso Kim South Korea	25	1.2k 0.9×	710 1.1×	276 0.8×	95 0.3×	248 1.0×	87	1.7k
Fotios Siannis United Kingdom	17	659 0.5×	513 0.8×	249 0.7×	113 0.3×	132 0.5×	22	1.5k
Marta Gil-Martín Spain	20	1.2k 0.9×	526 0.8×	228 0.7×	324 1.0×	136 0.6×	108	2.0k

Countries citing papers authored by Alice Chen

Since Specialization

Citations

This map shows the geographic impact of Alice Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alice Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alice Chen more than expected).

Fields of papers citing papers by Alice Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alice Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alice Chen. The network helps show where Alice Chen may publish in the future.

Co-authorship network of co-authors of Alice Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Alice Chen. A scholar is included among the top collaborators of Alice Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alice Chen. Alice Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Gillen, J., Austin Miller, Katherine M. Bell‐McGuinn, et al.. (2021). Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study. Gynecologic Oncology. 161(2). 512–515. 5 indexed citations

Jamy, Omer, Alice Chen, Liton Francisco, et al.. (2021). Impact of access to care on 1-year mortality following allogeneic blood or marrow transplantation. Bone Marrow Transplantation. 56(6). 1364–1372. 5 indexed citations

Buja, L. Maximilian, Giulia Ottaviani, Milica Ilić, et al.. (2019). Clinicopathological manifestations of myocarditis in a heart failure population. Cardiovascular Pathology. 45. 107190–107190. 10 indexed citations

Kuo, Frank C., Jonathan Park, K. Martin Chow, Alice Chen, & Matthew K. Walsworth. (2019). Avoiding peripheral nerve injury in arterial interventions. Diagnostic and Interventional Radiology. 25(5). 380–391. 18 indexed citations

Gopalakrishnan, Mathangi, Ivana Gojo, Judith E. Karp, et al.. (2018). Population pharmacokinetics and exposure–response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias. Cancer Chemotherapy and Pharmacology. 83(2). 319–328. 5 indexed citations

Klein, Kimberly, Alice Chen, Paul Allison, et al.. (2017). Intra-Pericardial Use of Recombinant Factor VIIa in a Patient With Acute Hemorrhagic Pericardial Effusion Following Transcutaneous Aortic Valve Replacement—A Case Report. Laboratory Medicine. 48(3). 262–265.

Seymour, Lesley, Jan Bogaerts, Andrea Perrone, et al.. (2017). iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. The Lancet Oncology. 18(3). e143–e152. 1528 indexed citations breakdown →

Chen, Alice, et al.. (2017). Representation of Women and Minorities in Clinical Trials for New Molecular Entities and Original Therapeutic Biologics Approved by FDA CDER from 2013 to 2015. Journal of Women s Health. 27(4). 418–429. 30 indexed citations

Conley, Barbara A., Robert J. Gray, Alice Chen, et al.. (2016). Abstract CT101: NCI-molecular analysis for therapy choice (NCI-MATCH) clinical trial: interim analysis. Cancer Research. 76(14_Supplement). CT101–CT101. 9 indexed citations

10.

Kummar, Shivaani, Geraldine O’Sullivan Coyne, Barış Türkbey, et al.. (2015). Phase II trial of PF-03084014 in adults with desmoid tumors/aggressive fibromatosis.. Journal of Clinical Oncology. 33(15_suppl). 10563–10563. 6 indexed citations

11.

Jeong, Woondong, Sook Ryun Park, Annamaria Rapisarda, et al.. (2013). Abstract 2416: Weekly EZN-2208 (pegylated SN-38) in combination with bevacizumab in patients with refractory solid tumors.. Cancer Research. 73(8_Supplement). 2416–2416. 1 indexed citations

12.

Mitchell, Sandra A., Christine Nichols, Steven B. Clauser, et al.. (2012). Validation of the NCI patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in women receiving treatment for metastatic breast cancer.. Journal of Clinical Oncology. 30(15_suppl). 9144–9144. 2 indexed citations

13.

Lacouture, Mario E., Michael L. Maitland, Siegfried Segaert, et al.. (2010). A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Supportive Care in Cancer. 18(4). 509–522. 107 indexed citations

14.

Murgo, Anthony J., Shivaani Kummar, Larry Rubinstein, et al.. (2008). Designing Phase 0 Cancer Clinical Trials. Clinical Cancer Research. 14(12). 3675–3682. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact